tirzepatide Archives -

Denmark’s Novo Nordisk has been almost single-handedly rebuilding the market for drugs to treat obesity over the last

Lilly fires a broadside at Novo Nordisk’s obesity ambitions

https://pharmaphorum.com/news/lilly-fires-a-broadside-at-novo-nordisks-obesity-ambitions/

Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which

FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovy

https://pharmaphorum.com/news/fda-ends-obesity-drug-drought/

Eli Lilly has scored five out of five with its phase 3 trials of type 2 diabetes candidate

Trial win sets up filings for Lilly’s diabetes blockbuster hope tirzepatide

https://pharmaphorum.com/news/final-trial-win-sets-up-filings-for-lillys-diabetes-blockbuster-hope-tirzepatide/

Eli Lilly’s decision to throw large amounts of research dollars at its next-generation diabetes drug tirzepatide could be

Lilly surges on positive phase 3 readout from diabetes contender

https://pharmaphorum.com/news/lilly-surges-on-positive-phase-3-readout-from-diabetes-contender/

tirzepatide